Clinical Trial

Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the effect of different doses of flumazenil antagonism on remimazolam plasma concentration in patients undergoing renal transplantation under general anesthesia.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06531369
Lead Sponsor Qianfoshan Hospital
Conditions Flumazenil to Antagonize Remimazolam, Remimazolam, Renal Transplantation
Enrollment 60 participants
Start Date 2024-07
Primary Completion 2025-12 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2024-08-01